IND Application submitted to the FDA for Ph 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations September 7, 2022
EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer June 14, 2022
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions June 14, 2022
MHRA and Research Ethics Committee Approvals Received to Initiate Ph 2B/3 AML Trials of OmnImmune March 24, 2022
FDA Clearance to Proceed with Ph 1b/2 Trial of ADG126 SAFEbody® in Combination with Pembrolizumab Announced March 17, 2022
FDA Clears IND for Phase 1b/2 Trial of ADG116 in Combination with Pembrolizumab in Patients with Solid Tumors November 30, 2021
